{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"71"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"664"},{"groupId":"OG001","value":"670"}],"units":"Participants"}],"description":"CR rate at the end of frontline therapy per IRF was defined as the percentage of participants who achieved CR at the end of frontline therapy that is after completion of either randomized regimen or alternate frontline therapy as determined by an IRF. CR was defined as disappearance of all evidence of disease.","groups":[{"description":"Brentuximab vedotin 1.2 milligram per kilogram (mg/kg), infusion, intravenously over 30-minutes plus doxorubicin 25 milligram per square meter (mg/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles. Brentuximab vedotin was administered within approximately 1 hour after completion of AVD.","id":"OG000","title":"A+AVD"},{"description":"Doxorubicin 25 mg/m\\^2, bleomycin 10 units per square meter (units/m\\^2), vinblastine 6 mg/m\\^2, and dacarbazine 375 mg/m\\^2, infusion, intravenously, once on Days 1 and 15 of each 28-day treatment cycle for up to a maximum of 6 cycles.","id":"OG001","title":"ABVD"}],"paramType":"NUMBER","populationDescription":"The ITT population included all participants randomized to treatment.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of frontline therapy (approximately 4 years)","title":"Complete Remission (CR) Per IRF Rate at the End of Frontline Therapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}